These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 35041206)

  • 1. ABO blood group does not influence the level of anti-SARS-CoV-2 antibodies in convalescent plasma donors.
    Žiberna K; Jež M; Jazbec K; Mali P; Potokar UR; Rožman P
    Transfusion; 2022 Mar; 62(3):556-562. PubMed ID: 35041206
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Absence of correlation between ABO Rh(D) blood group and neutralizing antibody titers in SARS-CoV-2 convalescent plasma donors.
    Hirani R; Hoad V; Gosbell IB; Irving DO
    Transfusion; 2022 Feb; 62(2):292-297. PubMed ID: 34936102
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ABO blood group and SARS-CoV-2 antibody response in a convalescent donor population.
    Bloch EM; Patel EU; Marshall C; Littlefield K; Goel R; Grossman BJ; Winters JL; Shrestha R; Burgess I; Laeyendecker O; Shoham S; Sullivan D; Gehrie EA; Redd AD; Quinn TC; Casadevall A; Pekosz A; Tobian AAR
    Vox Sang; 2021 Aug; 116(7):766-773. PubMed ID: 33493365
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlation between ABO blood group and neutralizing anti-SARS-CoV-2 antibody titers in convalescent plasma donations.
    Franchini M; Mengoli C; Ballotari A; Glingani C
    Transfus Clin Biol; 2022 May; 29(2):186-187. PubMed ID: 34690072
    [No Abstract]   [Full Text] [Related]  

  • 5. SARS-CoV-2 neutralizing capacity among blood donors without prior COVID-19 symptomatic history vs. blood donors with prior COVID-19 symptomatic history: A comparative study.
    Ravula U; Chunchu SR; Mooli S; Naik R; Sarangapati PRR
    Transfus Clin Biol; 2022 May; 29(2):107-111. PubMed ID: 35167958
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SARS COV-2- IgG antibodies in blood donors in pandemic - A game changer for policy makers.
    Mahapatra S
    Transfus Clin Biol; 2022 Feb; 29(1):11-15. PubMed ID: 34653615
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blood group O convalescent plasma donations have significantly lower levels of SARS-CoV-2 IgG antibodies compared to blood group A donations.
    Hayes C; Rubenstein W; Gibb D; Klapper E; Tanaka J; Pepkowitz S
    Transfusion; 2021 Aug; 61(8):2245-2249. PubMed ID: 34036595
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Production of anti-SARS-CoV-2 hyperimmune globulin from convalescent plasma.
    Vandeberg P; Cruz M; Diez JM; Merritt WK; Santos B; Trukawinski S; Wellhouse A; Jose M; Willis T
    Transfusion; 2021 Jun; 61(6):1705-1709. PubMed ID: 33715160
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-A and SARS-CoV-2: an intriguing association.
    de Freitas Dutra V; Bonet-Bub C; Yokoyama APH; Achkar R; Machado RRG; Assunção M; Candelária G; Soares CP; Fachini RM; Fontão-Wendel R; Hamerschlak N; Reis LFL; Araujo DB; Nudelman V; Pinho JRR; Rizzo LV; Sakashita AM; Scuracchio P; Durigon EL; Wendel S; Kutner JM
    Vox Sang; 2021 May; 116(5):557-563. PubMed ID: 33650690
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Seroprevalence of SARS-CoV-2 among potential convalescent plasma donors and analysis of their deferral pattern: Experience from tertiary care hospital in western India.
    Jain R; Mallya MV; Amoncar S; Palyekar S; Adsul HP; Kumar R; Chawla S
    Transfus Clin Biol; 2022 Feb; 29(1):60-64. PubMed ID: 34302953
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical predictors of donor antibody titre and correlation with recipient antibody response in a COVID-19 convalescent plasma clinical trial.
    Madariaga MLL; Guthmiller JJ; Schrantz S; Jansen MO; Christensen C; Kumar M; Prochaska M; Wool G; Durkin-Celauro A; Oh WH; Trockman L; Vigneswaran J; Keskey R; Shaw DG; Dugan H; Zheng NY; Cobb M; Utset H; Wang J; Stovicek O; Bethel C; Matushek S; Giurcanu M; Beavis KG; di Sabato D; Meltzer D; Ferguson MK; Kress JP; Shanmugarajah K; Matthews JB; Fung JF; Wilson PC; Alverdy JC; Donington JS
    J Intern Med; 2021 Apr; 289(4):559-573. PubMed ID: 33034095
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Persistence of SARS-CoV-2 total immunoglobulins in a series of convalescent plasma and blood donors.
    Martin MC; Jimenez A; Ortega N; Parrado A; Page I; Gonzalez MI; Blanco-Peris L
    PLoS One; 2022; 17(2):e0264124. PubMed ID: 35202394
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Demographic and Clinical Factors Associated with Reactivity of Anti-SARS-CoV-2 Antibodies in Serbian Convalescent Plasma Donors.
    Grujić J; Bujandrić N; Budakov-Obradović Z; Dolinaj V; Bogdan D; Savić N; Cabezas-Cruz A; Mijatović D; Simin V; Anđelić N; Banović P
    Int J Environ Res Public Health; 2021 Dec; 19(1):. PubMed ID: 35010301
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Convalescent plasma donors show enhanced cross-reactive neutralizing antibody response to antigenic variants of SARS-CoV-2 following immunization.
    Harvala H; Nguyen D; Simmonds P; Lamikanra AA; Tsang HP; Otter A; Maes P; Webster M; Clarkson A; Kaloyirou F; Hopkins V; Laidlaw SM; Carroll M; Mora A; Griffiths A; MacLennan S; Estcourt L; Roberts DJ
    Transfusion; 2022 Jul; 62(7):1347-1354. PubMed ID: 35588314
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Convalescent plasma for COVID-19: Donor demographic factors associated high neutralising antibody titres.
    Mehew J; Johnson R; Roberts D; Griffiths A; Harvala H
    Transfus Med; 2022 Aug; 32(4):327-337. PubMed ID: 35434868
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factors related to the development of high antibody titres against SARS-CoV-2 in convalescent plasma donors from the ConPlas-19 trial.
    Romera Martínez I; Avendaño-Solá C; Villegas Da Ros C; Bosch Llobet A; García Erce JA; González Fraile MI; Guerra Domínguez L; Vicuña Andrés I; Anguita Velasco J; González Rodríguez VP; Contreras E; Urcelay Uranga S; Pajares Herraiz ÁL; Jimenez-Marco T; Ojea Pérez AM; Arroyo Rodríguez JL; Pérez-Olmeda M; Ramos-Martínez A; Velasco-Iglesias A; Bueno Cabrera JL; Duarte RF
    Vox Sang; 2024 Jan; 119(1):27-33. PubMed ID: 37986640
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Case Report: Serial Cases: Prolongation of High Immunoglobulin G Level in Repetitive COVID-19 Convalescence Plasma Donor in Saiful Anwar Hospital Malang, Indonesia.
    Nurarifah N; Brahmantyo HP; Wardhani SO; Hermanto DH; Arsana PM
    Front Immunol; 2021; 12():633323. PubMed ID: 34790190
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characteristics of US Blood Donors Testing Reactive for Antibodies to SARS-CoV-2 Prior to the Availability of Authorized Vaccines.
    Dodd RY; Spencer BR; Xu M; Foster GA; Saá P; Brodsky JP; Stramer SL
    Transfus Med Rev; 2021 Jul; 35(3):1-7. PubMed ID: 34373145
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A trend of dropping anti-SARS-CoV-2 plaque reduction neutralization test titers over time in Canadian convalescent plasma donors.
    Drews SJ; Devine DV; McManus J; Mendoza E; Manguiat K; Wood H; Girardin R; Dupuis A; McDonough K; Drebot M
    Transfusion; 2021 May; 61(5):1440-1446. PubMed ID: 33734448
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Convalescent plasma therapy for the treatment of patients with COVID-19: Assessment of methods available for antibody detection and their correlation with neutralising antibody levels.
    Harvala H; Robb ML; Watkins N; Ijaz S; Dicks S; Patel M; Supasa P; Wanwisa D; Liu C; Mongkolsapaya J; Bown A; Bailey D; Vipond R; Grayson N; Temperton N; Gupta S; Ploeg RJ; Bolton J; Fyfe A; Gopal R; Simmonds P; Screaton G; Thompson C; Brooks T; Zambon M; Miflin G; Roberts DJ
    Transfus Med; 2021 Jun; 31(3):167-175. PubMed ID: 33333627
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.